Comparative Pharmacology
Head-to-head clinical analysis: MICONAZOLE 7 versus NYSTEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICONAZOLE 7 versus NYSTEX.
MICONAZOLE 7 vs NYSTEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and lead to leakage of intracellular contents and cell death.
Apply 200 mg (one full applicator) intravaginally once daily at bedtime for 7 days.
Topical: Apply thin layer to affected area twice daily. Oral suspension (nystatin): 500,000-1,000,000 units (5-10 mL) four times daily for candidiasis. Vaginal tablets: 1 tablet (100,000 units) intravaginally once daily for 14 days.
None Documented
None Documented
Terminal half-life 24-30 hours; prolonged in hepatic impairment
Variable; estimated 2-5 hours for systemic absorption (if any), but negligible systemic levels due to poor absorption.
Primarily fecal (~50%) and renal (~<1% unchanged)
Primarily fecal (>95%) as unchanged drug; minimal renal excretion (<1%).
Category A/B
Category C
Antifungal
Antifungal